WO2000075659A1 - Antibodies to nucleus pulposus in disc herniation, diagnostic kit, medical preparations and treatment - Google Patents

Antibodies to nucleus pulposus in disc herniation, diagnostic kit, medical preparations and treatment Download PDF

Info

Publication number
WO2000075659A1
WO2000075659A1 PCT/SE2000/001179 SE0001179W WO0075659A1 WO 2000075659 A1 WO2000075659 A1 WO 2000075659A1 SE 0001179 W SE0001179 W SE 0001179W WO 0075659 A1 WO0075659 A1 WO 0075659A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleus pulposus
antibodies
disc herniation
antibody
cells
Prior art date
Application number
PCT/SE2000/001179
Other languages
French (fr)
Inventor
Kjell Olmarker
Björn Rydevik
Original Assignee
A+Science Invest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A+Science Invest Ab filed Critical A+Science Invest Ab
Priority to AU54373/00A priority Critical patent/AU5437300A/en
Publication of WO2000075659A1 publication Critical patent/WO2000075659A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the present invention relates the use of serum antibodies for the diagnosis and treatment of disc herniation with resulting nerve root pain in the cervical and lumbar spine such as sciatica.
  • the object of the present invention is to obtain improved methods in diagnosis and treatment of nerve root pain such as sciatica and other radiculopathies related to disc herniation in the cervical or lumbar spine.
  • nucleus pulposus since the nucleus pulposus is secluded from the immune-system from birth, being a non-vascularized tissue, the immune system has not regarded the nucleus pulposus as "self during early embryonic stages, but would instead consider the nucleus pulposus as "non-self later in life (15-22).
  • possible antigens in the nucleus pulposus might thus be presented to the immune system and there would be an auto-immune reaction induced towards these antigens.
  • the reaction would mainly involve the nucleus pulposus, but the substances might also induce changes in the adjacent nerve roots secondary to this reaction.
  • These suggested substances would most likely be the same pro-inflammatory cytokines as previously being defined as inducing nerve root injury.
  • Ketalar R ketamine 50 mg/ml, Parke-Davis, Morris Plains, NJ
  • Hypnodil R metalhomidate chloride 50 mg/ml, AB Leo, Helsingborg, Sweden
  • Stresnil R azaperon, 2 mg/ml, Janssen Pharmaceutica, Beerse, Belgium
  • the pig was killed by an overdose of potassium chloride.
  • the lumbar and lower part of the thoracic spine was removed en bloc.
  • the spine was cleansed from muscles and tendons.
  • the discs were incised and the nucleus pulposus was harvested.
  • the nucleus pulposus (NP) was washed once in Ham's F12 medium (Gibco BRL, Paisley, Scotland).
  • the NP from discs were placed in a test tube with Ham's F12 medium and centrifuged. The remaining pellet was dissolved in 6 ml of Ham's F12 with 3 ml of trypsine 2.5 % in a 75 cm 2 culture flask for 30 minutes at 37°C.
  • Fungizone 2 ⁇ g/ml and ⁇ -ascorbic acid 50 ⁇ g/ml was added.
  • the cells were cultured in 25 cm 2 flasks (Costar, Cambridge, MA), at 37°C and 5% CO 2 in air for 3-4 weeks . After 2 weeks the cells were transferred to 4-chamber polystyrene vessel tissue culture treated glass slides (Becton Dickinson Labware, Franklin Lakes, NJ). Following 3 days of culture the slides were used for the assessment as will be described below.
  • a 2x2 cm big piece of the skin was harvested at the same time as the nucleus pulposus under sterile conditions.
  • the dermis of the skin was cut in small pieces and put in spinner bottles with 10 ml of collagenase solution (0.8 mg/ml, Sigma Chemical, St. Louis, MO, in Ham's F12 medium) for 90 minutes in 37°C water bath.
  • the separated fibroblasts were centrifuged and transferred to 75 cm 2 tissue culture flasks (Costar, Cambridge, MA), with DMEM/F12 1:1 medium supplemented as above for NP-cells.
  • the cultured fibroblasts were liberated from the culture flasks by treatment of 0.125% trypsine solution (Gibco BRL, Paisley, Scotland) and added to the serum.
  • the addition of fibroblasts was performed in order to eliminate the risk that antibodies in the serum which non-specifically would bind to cultured cells, would be applied to the nucleus pulposus cells.
  • the test-tube was centrifuged and the supernatant collected (serum with remaining antibodies).
  • the culture slides with the cultured nucleus pulposus cells were fixed in acetone for 10 minutes and then dried in air.
  • the slides were washed twice for 5 minutes in PBS (Phosphate Buffered Saline, Life Technologies Ltd., Paisley, Scotland)
  • the slides were then treated with 0.3% H2O2 (Sigma Chemical, St. Louis, MO) for 30 minutes and then washed twice for 5 minutes in PBS.
  • the slides were then exposed to standard freeze-dried milk (5% in PBS) for 30 minutes to block irrelevant antigens, and then washed twice for 5 minutes in PBS.
  • the cultured NP-cells were exposed to a) one drop of the pretreated serum, b) one drop of the pretreated serum diluted by PBS 1:40; or c) not in serum at all, and incubated for 1 hr at room temperature, and then washed twice for 5 minutes in PBS.
  • the culture slides were then incubated with the secondary antibody (Peroxidase-Conjugated Rabbit Anti-Swine immunoglobulin, Code No. P164, Dako A/S, Glostrup, Denmark) for 30 minutes, and then washed twice for 5 minutes in PBS.
  • the slides were finally developed with DAB (3,3'-diaminobenzidine, 10 mg in 5 ml PBS, and 17 ⁇ l H 2 O 2 (3%), Sigma Chemical, St. Louis, MO) for 2 minutes, and then washed twice for 5 minutes in PBS.
  • DAB 3,3'-diaminobenzidine, 10 mg in 5 ml PBS, and 17 ⁇ l H 2 O 2 (3%), Sigma Chemical, St. Louis, MO
  • the specimens were dehydrated in a series of alcohol-dilutions and assessed by light microscopy.
  • the antigen may be a potent antigen, comparable for instance to the MHC (Major Histocompatibility Complex)antigens.
  • the present invention can thus be used in the form of an antigen containing diagnostic kit for diagnosing disc herniation, in particular disc herniation leading to sciatica.
  • an antigen containing diagnostic kit for diagnosing disc herniation, in particular disc herniation leading to sciatica.
  • serum antibodies towards the nucleus pulposus cells can be neutralized in three ways. First the NP-antibodies can be inactivated by administering a specific antibody for such serum antibodies, an anti-antibody.
  • the effects of the NP-antibodies can be inhibited by administering a substance that is similar to the NP- antibody, a false antibody, and binds to the antigen in the nucleus pulposus in stead of the antibody, which false antibody is able to bind to and block the antigen in such a way that an immunological reaction is inhibited.
  • soluble antigens corresponding to the NP- antibodies can be administered, thereby blocking the effects of the NP-antibodies. In such ways the action of the NP-antibodies can be blocked since the NP-antibodies are prevented from binding to its antigen.
  • the compounds of the invention can be administered in a variety of dosage forms, e.g, orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions; rectally, in the form of suppositories; parenterally, e.g., intramuscularly or by intravenous injection or infusion.
  • the therapeutic regimen for the different clinical syndromes must be adapted to the type of pathology taken in to account, as usual, also the route of administration, the form in which the compound is administered and age, weight, and condition of the subject involved.
  • the oral route is employed, in general, for all conditions, requiring such compounds.
  • preference is given to intravenous injection.
  • the compounds of the invention can be administered orally at doses ranging from about 20 to about 1500 mg/day.
  • these dosage regimens may be adjusted to provide the optimal therapeutic response.
  • compositions containing the compounds of the invention in association with pharmaceutically acceptable carriers or diluents will, of course, depend upon the desired route of administration.
  • the composition may be formulated in the conventional manner with the usual ingredients.
  • the compounds of the invention may be administered in the form of aqueous or oily solutions or suspensions, tablets, pills, gelatine capsules (hard or soft ones)syrups, drops or suppositories.
  • the pharmaceutical compositions containing the compounds of the invention are preferably tablets, pills or gelatine capsules, which contain the active substance together with diluents, such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose; lubricants, e.g., silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; or they may also contain binders, such as starches, gelatine, methyl cellulose, carboxymefhylcellulose, gum arabic, tragacanth, polyvinylpyrrolidone; disaggregating agents such as starches, alginic acid, alginates, sodium starch glycolate, microcrystalline cellulose; effervescing agents such a carbonates and acids; dyestoffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and in general non-toxic and pharmaceutically inert substances
  • compositions may be manufactured in known manners, e.g., by means of mixing, granulating, tableting, sugar-coating or film-coating processes.
  • film providing compounds can be selected to provide release in the right place in the intestinal tract with regard to absorption and maximum effect.
  • pH-dependent film formers can be used to allow absorption in the intestines as such, whereby different phthalate are normally used or acrylic acid/methacrylic acid derivatives and polymers.
  • liquid dispersions for oral administration may be e.g., syrups, emulsion, and suspensions.
  • the syrups may contain as carrier, e.g., saccharose, or saccharose with glycerine and/or mannitol and/or sorbitol.
  • Suspensions and emulsions may contain as carrier, e.g., a natural gum, such as gum arabic, xanthan gum, agar, sodium alginate, pectin, methyl cellulose, carboxymethylcellulose, polyvinyl alcohol.
  • a natural gum such as gum arabic, xanthan gum, agar, sodium alginate, pectin, methyl cellulose, carboxymethylcellulose, polyvinyl alcohol.
  • the suspension or solutions for intramuscular injections may contain together with the active compound, a pharmaceutically acceptable carrier, such as e.g., sterile water, olive oil, ethyl oleate, glycols,, e.g., propylene glycol, and if so desired, a suitable amount of lidocaine hydrochloride.
  • a pharmaceutically acceptable carrier such as e.g., sterile water, olive oil, ethyl oleate, glycols,, e.g., propylene glycol, and if so desired, a suitable amount of lidocaine hydrochloride.
  • Adjuvants for trigging the injection effect can be added as well.
  • the solutions for intravenous injection or infusion may contain as carrier, e.g., sterile water, or preferably, a sterile isotonic saline solution, as well as adjuvants used in the field of injection of active compounds.
  • carrier e.g., sterile water, or preferably, a sterile isotonic saline solution, as well as adjuvants used in the field of injection of active compounds.
  • the suppositories may contain together with the active compound, a pharmaceutically acceptable carrier, e.g., cocoa-butter polyethylene glycol, a polyethylene sorbitan fatty acid ester surfactant or lecithin.
  • a pharmaceutically acceptable carrier e.g., cocoa-butter polyethylene glycol, a polyethylene sorbitan fatty acid ester surfactant or lecithin.
  • Olmarker K Brisby H, Yabuki S, Nordborg C, Rydevik B. The effects of normal, frozen, and hyaluronidase-digested nucleus pulposus on nerve root structure and function. Spine 1997;22:4715; discussion 476. 6. Otani, K, Kikuchi, S, Arai, I, Mao GP, Konno, S, Olmarker, K: Experimental disc herniation. Evaluation of the natural course using assessment of changes in nerve conduction of the spinal nerve roots and MRI-changes of the intervertebral discs. Spine 22:24, 2894-90, 1997

Abstract

The present invention relates to antibodies towards nucleus pulposus cells and the use thereof for manufacturing a kit for diagnosing disc herniation, as well as anti-antibody to said antibody, and its use for treating disc herniation as well as sciatica, as well as a false antibody to the antibody to nucleus pulposus cells as well as soluble antigens form nucleus pulposus cells to block such said antibodies.

Description

TITLE
ANTIBODIES TO NUCLEUS PULPOSUS IN DISC HERNIATION, DIAGNOSTIC KIT, MEDICAL PREPARATIONS AND TREATMENT
DESCRIPTION Technical field
The present invention relates the use of serum antibodies for the diagnosis and treatment of disc herniation with resulting nerve root pain in the cervical and lumbar spine such as sciatica.
The object of the present invention is to obtain improved methods in diagnosis and treatment of nerve root pain such as sciatica and other radiculopathies related to disc herniation in the cervical or lumbar spine.
Background of the invention The exact pathophysiological mechanisms leading to sciatica in relation to herniation of intervertebral discs are not fully understood. Recently it was demonstrated that the nucleus pulposus (the viscous component of the intervertebral disc that leaks out into the spinal canal in case of disc herniation) may induce structural and functional changes in the adjacent nerve root (1-14). Also, it has been shown that nerve roots experimentally exposed to nucleus pulposus become sensitive to mechanical deformation thereby producing pain (8,13). Certain pro-inflammatory cytokines, produced by the nucleus pulposus cells, have been defined as being responsible for inducing these effects (10). However, there is both clinical and experimental evidence which may suggest that also immunologic mechanisms may be present to a certain extent. It has been suggested that, since the nucleus pulposus is secluded from the immune-system from birth, being a non-vascularized tissue, the immune system has not regarded the nucleus pulposus as "self during early embryonic stages, but would instead consider the nucleus pulposus as "non-self later in life (15-22). At disc herniation, possible antigens in the nucleus pulposus might thus be presented to the immune system and there would be an auto-immune reaction induced towards these antigens. The reaction would mainly involve the nucleus pulposus, but the substances might also induce changes in the adjacent nerve roots secondary to this reaction. These suggested substances would most likely be the same pro-inflammatory cytokines as previously being defined as inducing nerve root injury. There is reason to believe that such mechanisms also relates to radiculopathies in the upper extremities due to disc herniation in the cervical spine. However, no one has previously been able to demonstrate the presence of antibodies in serum towards the nucleus pulposus of the same individual.
In order to isolate and show the presence of antibodies towards nucleus pulposus cells the following experiments and tests were conducted.
Material and methods 1) Culture of nucleus pulposus cells:
One pig weighing 26 kg was anaesthetized with an intra muscular injection of 20 mg/kg body weight of KetalarR (ketamine 50 mg/ml, Parke-Davis, Morris Plains, NJ) and an intravenous injection of 4 mg/kg body weight of HypnodilR (methomidate chloride 50 mg/ml, AB Leo, Helsingborg, Sweden) and 0,1 mg/kg body weight of StresnilR (azaperon, 2 mg/ml, Janssen Pharmaceutica, Beerse, Belgium).
Approximately 20 ml of blood were collected and allowed to coagulate at room temperature. It was then centrifuged and the supernatant (serum) was stored at 80°C in a refrigerator.
After induction of anaesthesia, the pig was killed by an overdose of potassium chloride. The lumbar and lower part of the thoracic spine was removed en bloc. The spine was cleansed from muscles and tendons. Under sterile conditions the discs were incised and the nucleus pulposus was harvested. The nucleus pulposus (NP) was washed once in Ham's F12 medium (Gibco BRL, Paisley, Scotland).The NP from discs were placed in a test tube with Ham's F12 medium and centrifuged. The remaining pellet was dissolved in 6 ml of Ham's F12 with 3 ml of trypsine 2.5 % in a 75 cm2 culture flask for 30 minutes at 37°C. Then 6 ml of Ham's F12 with 12 mg of collagenase (Sigma Cat. No. C9407) were added. After 3.5 hrs at 37°C the content of the culture flask was transferred to a test tube and centrifuged. The separated NP-cell pellets were suspended in DMEM/F12 1 : 1 medium (Gibco BRL, Paisley, Scotland) supplemented with 1% L-glutamine (200 mM, Gibco BRL, Paisley, Scotland), 50 μg/ml gentamycine sulphate (Gibco BRL, Paisley, Scotland) and 10% foetal calf serum (FCS, Gibco BRL, Paisley, Scotland). Fungizone 2 μg/ml and α-ascorbic acid 50 μg/ml was added. The cells were cultured in 25 cm2 flasks (Costar, Cambridge, MA), at 37°C and 5% CO2 in air for 3-4 weeks . After 2 weeks the cells were transferred to 4-chamber polystyrene vessel tissue culture treated glass slides (Becton Dickinson Labware, Franklin Lakes, NJ). Following 3 days of culture the slides were used for the assessment as will be described below.
2) Culture of fibroblasts
A 2x2 cm big piece of the skin was harvested at the same time as the nucleus pulposus under sterile conditions. The dermis of the skin was cut in small pieces and put in spinner bottles with 10 ml of collagenase solution (0.8 mg/ml, Sigma Chemical, St. Louis, MO, in Ham's F12 medium) for 90 minutes in 37°C water bath. The separated fibroblasts were centrifuged and transferred to 75 cm2 tissue culture flasks (Costar, Cambridge, MA), with DMEM/F12 1:1 medium supplemented as above for NP-cells.
3) Pretreatment of the serum
The cultured fibroblasts were liberated from the culture flasks by treatment of 0.125% trypsine solution (Gibco BRL, Paisley, Scotland) and added to the serum. The addition of fibroblasts was performed in order to eliminate the risk that antibodies in the serum which non-specifically would bind to cultured cells, would be applied to the nucleus pulposus cells. The test-tube was centrifuged and the supernatant collected (serum with remaining antibodies).
4). Assessment of the presence of antibodies in serum towards autologous nucleus pulposus cells
The culture slides with the cultured nucleus pulposus cells were fixed in acetone for 10 minutes and then dried in air. The slides were washed twice for 5 minutes in PBS (Phosphate Buffered Saline, Life Technologies Ltd., Paisley, Scotland) The slides were then treated with 0.3% H2O2 (Sigma Chemical, St. Louis, MO) for 30 minutes and then washed twice for 5 minutes in PBS. The slides were then exposed to standard freeze-dried milk (5% in PBS) for 30 minutes to block irrelevant antigens, and then washed twice for 5 minutes in PBS. The cultured NP-cells were exposed to a) one drop of the pretreated serum, b) one drop of the pretreated serum diluted by PBS 1:40; or c) not in serum at all, and incubated for 1 hr at room temperature, and then washed twice for 5 minutes in PBS. The culture slides were then incubated with the secondary antibody (Peroxidase-Conjugated Rabbit Anti-Swine immunoglobulin, Code No. P164, Dako A/S, Glostrup, Denmark) for 30 minutes, and then washed twice for 5 minutes in PBS. The slides were finally developed with DAB (3,3'-diaminobenzidine, 10 mg in 5 ml PBS, and 17 μl H2O2 (3%), Sigma Chemical, St. Louis, MO) for 2 minutes, and then washed twice for 5 minutes in PBS. The specimens were dehydrated in a series of alcohol-dilutions and assessed by light microscopy.
Results a) Pretreated serum
There was a clear staining of the cell membranes of the nucleus pulposus cells and also of the nuclei of the cells. This indicates the presence of specific antibodies towards the nucleus pulposus cells in serum from the same individual (autologous).
b) Pretreated serum at 1 :40
There was a similar staining of the cells as for the concentrated serum, although not as pronounced.
c) Nucleus pulposus cells not exposed to serum There was no staining of the cells and the cells were difficult to distinguish on the culture slides. This suggests that the secondary antibody (rabbit: anti-swine-immunoglobulin) did not non-specifically bind to the pig nucleus pulposus cells and that the staining of a) and b) was the result of the addition of specific antibodies from the serum.
Conclusion and comments
The following conclusion can be made from the present experiment:
- There are antibodies present in serum that specifically bind to nucleus pulposus cells of the same individual
The following comments can be made from the present experiment
- From this study it can not be recognized if the antibodies are readily available in high concentrations in serum or if there had been an immunization to the nucleus pulposus in the pig. If there are antibodies already present in the serum, the antigen may be a potent antigen, comparable for instance to the MHC (Major Histocompatibility Complex)antigens.
- Regardless of the nature of the antigen one can suspect that the levels in serum may increase the levels of these antibodies in case of disc herniation and sciatica and therefore used as a diagnostic tool.
- At present the diagnosis of sciatica is made by patient history and radiologic findings. However, since it is known that almost 30% of the population without any complaints of sciatica also have disc herniations at radiological examinations, the radiologic diagnosis is less valuable (23-25). It has been suggested that disc herniations can be can be either active (symptoms) or inactive (no symptoms). Based on the findings in the present study it is assumed that an active disc herniation is related to inflammatory and immunologic changes, whereas the inactive disc herniation is a mere protrusion of disc tissue without triggering of the immune system. The lack of immunologic reaction might be based on either the nucleus pulposus still being isolated from the epidural space by remaining membranes or a less developed immunoreactivity of the patient, alternatively lack of sensitizing antigens in the disc cells.
The present invention can thus be used in the form of an antigen containing diagnostic kit for diagnosing disc herniation, in particular disc herniation leading to sciatica. Further the effects of serum antibodies towards the nucleus pulposus cells (NP-antibodies) can be neutralized in three ways. First the NP-antibodies can be inactivated by administering a specific antibody for such serum antibodies, an anti-antibody. Secondly, the effects of the NP-antibodies can be inhibited by administering a substance that is similar to the NP- antibody, a false antibody, and binds to the antigen in the nucleus pulposus in stead of the antibody, which false antibody is able to bind to and block the antigen in such a way that an immunological reaction is inhibited. Thirdly, soluble antigens corresponding to the NP- antibodies can be administered, thereby blocking the effects of the NP-antibodies. In such ways the action of the NP-antibodies can be blocked since the NP-antibodies are prevented from binding to its antigen.
The compounds of the invention can be administered in a variety of dosage forms, e.g, orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions; rectally, in the form of suppositories; parenterally, e.g., intramuscularly or by intravenous injection or infusion. The therapeutic regimen for the different clinical syndromes must be adapted to the type of pathology taken in to account, as usual, also the route of administration, the form in which the compound is administered and age, weight, and condition of the subject involved.
The oral route is employed, in general, for all conditions, requiring such compounds. In emergency cases preference is given to intravenous injection. For these purposes the compounds of the invention can be administered orally at doses ranging from about 20 to about 1500 mg/day. Of course, these dosage regimens may be adjusted to provide the optimal therapeutic response.
The nature of the pharmaceutical composition containing the compounds of the invention in association with pharmaceutically acceptable carriers or diluents will, of course, depend upon the desired route of administration. The composition may be formulated in the conventional manner with the usual ingredients. For example, the compounds of the invention may be administered in the form of aqueous or oily solutions or suspensions, tablets, pills, gelatine capsules (hard or soft ones)syrups, drops or suppositories.
Thus for oral administration, the pharmaceutical compositions containing the compounds of the invention are preferably tablets, pills or gelatine capsules, which contain the active substance together with diluents, such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose; lubricants, e.g., silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; or they may also contain binders, such as starches, gelatine, methyl cellulose, carboxymefhylcellulose, gum arabic, tragacanth, polyvinylpyrrolidone; disaggregating agents such as starches, alginic acid, alginates, sodium starch glycolate, microcrystalline cellulose; effervescing agents such a carbonates and acids; dyestoffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and in general non-toxic and pharmaceutically inert substances used in the formulation of pharmaceutical compositions. The mentioned pharmaceutical compositions may be manufactured in known manners, e.g., by means of mixing, granulating, tableting, sugar-coating or film-coating processes. In the case film providing compounds can be selected to provide release in the right place in the intestinal tract with regard to absorption and maximum effect. Thus pH- dependent film formers can be used to allow absorption in the intestines as such, whereby different phthalate are normally used or acrylic acid/methacrylic acid derivatives and polymers.
The liquid dispersions for oral administration may be e.g., syrups, emulsion, and suspensions.
The syrups may contain as carrier, e.g., saccharose, or saccharose with glycerine and/or mannitol and/or sorbitol.
Suspensions and emulsions may contain as carrier, e.g., a natural gum, such as gum arabic, xanthan gum, agar, sodium alginate, pectin, methyl cellulose, carboxymethylcellulose, polyvinyl alcohol.
The suspension or solutions for intramuscular injections may contain together with the active compound, a pharmaceutically acceptable carrier, such as e.g., sterile water, olive oil, ethyl oleate, glycols,, e.g., propylene glycol, and if so desired, a suitable amount of lidocaine hydrochloride. Adjuvants for trigging the injection effect can be added as well.
The solutions for intravenous injection or infusion may contain as carrier, e.g., sterile water, or preferably, a sterile isotonic saline solution, as well as adjuvants used in the field of injection of active compounds.
The suppositories may contain together with the active compound, a pharmaceutically acceptable carrier, e.g., cocoa-butter polyethylene glycol, a polyethylene sorbitan fatty acid ester surfactant or lecithin. REFERENCES
I. Olmarker K, Rydevik B, Nordborg C. Autologous nucleus pulposus induces neurophysiologic and histologic changes in porcine cauda equina nerve roots [see comments]. Spine 1993;18:1425-32. 2. Olmarker K, Byrod G, Comefjord M, Nordborg C, Rydevik B. Effects of methylprednisolone on nucleus pulposus-induced nerve root injury. Spine 1994; 19:1803-8.
3. Olmarker K, Nordborg C, Larsson K, Rydevik B. Ultrastructural changes in spinal nerve roots induced by autologous nucleus pulposus. Spine 1996;21:411-4.
4. Kayama S, Konno S, Olmarker K, Yabuki S, Kikuchi S. Incision of the anulus fibrosis induces nerve root moφhologic, vascular, and functional changes. An experimental study.
Spine 1996:21 :2539-43.
5. Olmarker K, Brisby H, Yabuki S, Nordborg C, Rydevik B. The effects of normal, frozen, and hyaluronidase-digested nucleus pulposus on nerve root structure and function. Spine 1997;22:4715; discussion 476. 6. Otani, K, Kikuchi, S, Arai, I, Mao GP, Konno, S, Olmarker, K: Experimental disc herniation. Evaluation of the natural course using assessment of changes in nerve conduction of the spinal nerve roots and MRI-changes of the intervertebral discs. Spine 22:24, 2894-90, 1997
7. Kayama S, Olmarker K, Larsson K, Sjδgren-Jansson E, Lindahl A, Rydevik B. Cultured, autologous nucleus pulposus cells induce structural and functional changes in spinal nerve roots. Spine 23:20, 2155-8, 1998
8. Olmarker K, Myers RR. Pathogenesis of sciatic pain: Role of herniated nucleus pulposus and deformation of spinal nerve root and DRG. PAIN, 78:9, 105, 1998
9. Yabuki S, Kawaguchi Y, Olmarker K, Rydevik B. Effects of lidocaine on nucleus pulposus-induced nerve root injury. Spine, 23:22, 2383-9, 1998
10. Olmarker, K, Larsoon, K:TNFa and nucleus pulposus-induced nerve root injury. Spine 23:23, 2538-44, 1998
I I. Byrδd, G, Olmarker, K, Nordborg, C, Rydevik, B: Early effects of nucleus pulposus application on spinal nerve root morphology and function. Eur Spine J. 7, 445-49, 1998 12. Yabuki, S, Kikuchi, S, Olmarker, K, Myers RR: Acute effects of nucleus pulposus on blood flow and endoneurial fluid pressure in rat dorsal root ganglia. Spine 23:23, 2517-23, 13. Olmarker K, lwabuchi M, Larsson K, Rydevik B. Effects of in vitro degenerated nucleus pulposus on nerve root conduction velocity. Eur Spine Journal, 7:5, 394-9, 1998
14. Otani K, Mao GP, Arai I, Konno S, Olmarker K, Kikuchi S. Nucleus pulposus-induced increase in vascular permeability in the nerve root. Manuscript 15. Bobechko, WP, Hirsch, C: Auto-immune response to nucleus pulposus in the rabbit. J Bone Joint Surg. 47 B 3, 574-580, 1965
16. LaRocca, H: New horizons in research in disc disease. Orthop Clin N Am, 2, 521, 1971
17. Naylor, A: Biochemical changes in human intervertebral disc degeneration and prolapse. Orthop Clin N Am, 2:2, 343, 1971 18. Gertzbein, SD, Tile, M, Gross, A, Falk, R: Autoi munity in degenerative disease of the lumbar spine. Orthop Clin N Am, 6:1, 67-73, 1975
19. Bisla, RS, Marchisello, PJ, Lockshin, MD, Hart, DM, Marcus, RE, Granda, J: Autoimmunological basis of disc degeneration. Clin Orthop, 123, 149-154, 1976
20. Gertzbein, SD: Degenerative disc disease of the lumbar spine. Immunological implications. Clin Orthop, 129:69-71, 1977
21. Gertzbein, SD, Tait JH, Devlin, SR: The stimulation of lymphocytes by nucleus pulposus in patients with degenerative disc disease of the lumbar spine. Clin Orthop, 123, 149-154, 1977
22. Olmarker, K: Experimental basis of sciatica, J Orthop Science, 1, 230-42, 1996 23. Boden, SD, Davis, DO, Dina, TS, Patronas, NJ, Wiesel, SW: Abnormal magnetic- resonance scans of the lumbar spine in symptomatic subjects. A prospective investigation. J Bone Joint Surg, 72:3, 403-8, 1990
24.Boos, N, Rieder, R, Schade, V, Spratt, KF, Semmer, N, Aebi, M: The diagnostic accuracy of magnetic resonance imaging, work perception and psychosocial factors in identifying symptomatic disc herniations. Spine, 20:24, 2613-25, 1995
25. Weishaupt, D, Zanetti, M, Hodler, J, Boos, N: MR imaging of the lumbar spine: prevalence of intervertebral disc extrusion and sequestration, nerve root compression, end plate abnormalities, and osteoarthritis of the facet joints in asymptomatic volunteers. Radiology, 209:3, 661-6, 1998. 26. Satoh, K, Konno, S, Nishiyama, K, Olmarker, K, Kikuchi, S: Presence and distribution of antigen-antibody complexes in the herniated nucleus pulposus. Submitted.

Claims

1. Kit for diagnosing disc herniation, characterized in that it comprises antigens from nucleus pulposus cells for determining an optional presence of antibodies to nucleus pulposus.
2. The use of an anti-antibody to antibodies to nucleus pulposus cells in the manufacture of a medicament for the treatment of disc herniation.
3. The use of a false antibody to nucleus pulposus cells in the manufacture of a medicament for the treatment of disc herniation, which false antibody is able to bind to and block the antigen in such a way that an immunological reaction is inhibited.
4. The use of soluble antigens from nucleus pulposus cells in the manufacture of a medicament or a diagnostic means for the diagnosis or treatment of disc herniation.
5. Method for treating disc herniation, whereby a therapeutically efficient amount of a compound that prevents the binding of serum antibodies to nucleus pulposus cells to bind to nucleus pulposus.
6. Method for treating disc herniation, whereby a therapeutically efficient amount of an anti- antibody to antibodies of nucleus pulposus cells is administered.
7. Method for treating disc herniation, whereby a therapeutically efficient amount of a false antibody to nucleus pulposus is administered, which false antibody is able to bind to and block the antigen in such a way that an immunological reaction is inhibited.
8. Method for treating disc herniation, whereby a therapeutically efficient amount of soluble antigens from nucleus pulposus cells is administered.
PCT/SE2000/001179 1999-06-09 2000-06-07 Antibodies to nucleus pulposus in disc herniation, diagnostic kit, medical preparations and treatment WO2000075659A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU54373/00A AU5437300A (en) 1999-06-09 2000-06-07 Antibodies to nucleus pulposus in disc herniation, diagnostic kit, medical preparations and treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902155-2 1999-06-09
SE9902155A SE9902155L (en) 1999-06-09 1999-06-09 Serum antibodies

Publications (1)

Publication Number Publication Date
WO2000075659A1 true WO2000075659A1 (en) 2000-12-14

Family

ID=20415987

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2000/001179 WO2000075659A1 (en) 1999-06-09 2000-06-07 Antibodies to nucleus pulposus in disc herniation, diagnostic kit, medical preparations and treatment

Country Status (3)

Country Link
AU (1) AU5437300A (en)
SE (1) SE9902155L (en)
WO (1) WO2000075659A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7318840B2 (en) 1999-12-06 2008-01-15 Sdgi Holdings, Inc. Intervertebral disc treatment devices and methods
US7713303B2 (en) 2002-09-18 2010-05-11 Warsaw Orthopedic, Inc. Collagen-based materials and methods for augmenting intervertebral discs
US7731981B2 (en) 2002-11-15 2010-06-08 Warsaw Orthopedic, Inc. Collagen-based materials and methods for treating synovial joints
US8118779B2 (en) 2006-06-30 2012-02-21 Warsaw Orthopedic, Inc. Collagen delivery device
US8399619B2 (en) 2006-06-30 2013-03-19 Warsaw Orthopedic, Inc. Injectable collagen material
WO2017176196A1 (en) * 2016-04-04 2017-10-12 Chalmers Ventures Ab Methods and compositions for the treatment of intervertebral disc herniation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628027A (en) * 1982-05-19 1986-12-09 Molecular Engineering Associates, Ltd. Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
WO1991008760A1 (en) * 1989-12-20 1991-06-27 Brigham And Women's Hospital Improved treatment of autoimmune diseases by aerosol administration of auto antigens
US5266564A (en) * 1989-06-02 1993-11-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. Method for treating certain autoimmune diseases
WO1994014070A1 (en) * 1992-12-04 1994-06-23 Shriners Hospitals For Crippled Children Immunoassay for the measurement of collagen cleavage in cartilage
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
WO1997002837A1 (en) * 1995-07-07 1997-01-30 Autoimmune, Inc. Method of treating rheumatoid arthritis with low dose type ii collagen
WO1998041865A1 (en) * 1997-03-19 1998-09-24 Montech Medical Developments Pty. Ltd. Method for the diagnosis of rheumatoid arthritis

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628027A (en) * 1982-05-19 1986-12-09 Molecular Engineering Associates, Ltd. Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5266564A (en) * 1989-06-02 1993-11-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. Method for treating certain autoimmune diseases
WO1991008760A1 (en) * 1989-12-20 1991-06-27 Brigham And Women's Hospital Improved treatment of autoimmune diseases by aerosol administration of auto antigens
WO1994014070A1 (en) * 1992-12-04 1994-06-23 Shriners Hospitals For Crippled Children Immunoassay for the measurement of collagen cleavage in cartilage
WO1997002837A1 (en) * 1995-07-07 1997-01-30 Autoimmune, Inc. Method of treating rheumatoid arthritis with low dose type ii collagen
WO1998041865A1 (en) * 1997-03-19 1998-09-24 Montech Medical Developments Pty. Ltd. Method for the diagnosis of rheumatoid arthritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S.D. GERTZBEIN, M.D.: "Degenerative disk disease of the lumbar spine: Immunological implications", CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, vol. 129, 1977, pages 68 - 71 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7318840B2 (en) 1999-12-06 2008-01-15 Sdgi Holdings, Inc. Intervertebral disc treatment devices and methods
US8349012B2 (en) 1999-12-06 2013-01-08 Warsaw Orthopedic, Inc. Intervertebral disc treatment devices and methods
US7713303B2 (en) 2002-09-18 2010-05-11 Warsaw Orthopedic, Inc. Collagen-based materials and methods for augmenting intervertebral discs
US7731981B2 (en) 2002-11-15 2010-06-08 Warsaw Orthopedic, Inc. Collagen-based materials and methods for treating synovial joints
US8118779B2 (en) 2006-06-30 2012-02-21 Warsaw Orthopedic, Inc. Collagen delivery device
US8399619B2 (en) 2006-06-30 2013-03-19 Warsaw Orthopedic, Inc. Injectable collagen material
WO2017176196A1 (en) * 2016-04-04 2017-10-12 Chalmers Ventures Ab Methods and compositions for the treatment of intervertebral disc herniation

Also Published As

Publication number Publication date
AU5437300A (en) 2000-12-28
SE9902155L (en) 2000-12-10
SE9902155D0 (en) 1999-06-09

Similar Documents

Publication Publication Date Title
Suzuki et al. Haemophilus parainfluenzae antigen and antibody in renal biopsy samples and serum of patients with IgA nephropathy
Haribhai et al. Spinal cord schistosomiasis: A clinical, laboratory and radiological study, with a note on herapeutic aspects
JP3203323B2 (en) Diagnosis and treatment of insulin-dependent diabetes
Makino et al. Heparan sulfate proteoglycans are lost in patients with diabetic nephropathy
Cope et al. Possible induction of systemic lupus erythematosus by human parvovirus.
Hersh et al. Paraneoplastic opsoclonus‐myoclonus associated with anti‐Hu antibody
KUROSE et al. Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats
Ballardie et al. Autoimmunity in IgA nephropathy
CN1192156A (en) Treatment of T cell mediated autoimmune disorders
Lopez et al. Serum autoantibodies in patients with Alzheimer's disease and vascular dementia and in nondemented control subjects.
Blair et al. Localization of infectious processes with gallium citrate Ga 67
Whitehouse et al. Macroglobulinemia and vasculitis in Sjögren's syndrome: Experimental observations relating to pathogenesis
RU2524630C2 (en) Application of apl peptide for treatment of inflammatory intestinal disease and type 1 diabetes
WO2000075659A1 (en) Antibodies to nucleus pulposus in disc herniation, diagnostic kit, medical preparations and treatment
US6569431B2 (en) Recombinant antibody fragments as autoantibody antagonists
Steck et al. Antibody testing in peripheral nerve disorders
US5529898A (en) Methods of detecting disorders of the central nervous system by detecting autoantibodies which specifically bind ionotropic glutamate receptors
AU2002211771A1 (en) Recombinant antibody fragments as autoantibody antagonists
EP1115425B1 (en) Autoantibody inhibitors
Díez‐Tejedor et al. Encephalopathy and biopsy‐proven cerebrovascular inflammatory changes in a cocaine abuser
Drew et al. Levamisole-associated neutropenia and autoimmune granulocytotoxins.
Ryba et al. Is vascular angiopathy following intracranial aneurysm rupture immunologically mediated?
Liozon et al. Absence of anti-beta2 glycoprotein I antibodies in giant cell arteritis: a study of 45 biopsy-proven cases.
Henneberg et al. Antibodies to brain tissue in sera of schizophrenic patients: preliminary findings
US7981619B2 (en) Composition for prevention, treatment, and diagnosis of chronic obstructive pulmonary disease (COPD)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09980784

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)